Compare ANDG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDG | SLN |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2025 | 2010 |
| Metric | ANDG | SLN |
|---|---|---|
| Price | $66.70 | $19.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $61.29 | $19.75 |
| AVG Volume (30 Days) | 411.5K | ★ 4.3M |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $838,692,000.00 | $559,000.00 |
| Revenue This Year | $18.38 | N/A |
| Revenue Next Year | $18.35 | $131.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.64 | N/A |
| 52 Week Low | $18.12 | $4.19 |
| 52 Week High | $68.41 | $19.87 |
| Indicator | ANDG | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 78.03 |
| Support Level | $52.10 | $13.01 |
| Resistance Level | $68.41 | $19.87 |
| Average True Range (ATR) | 2.53 | 0.07 |
| MACD | -0.14 | -0.20 |
| Stochastic Oscillator | 73.93 | 55.81 |
Andersen Group Inc is a provider of independent tax, valuation, and financial advisory services to individuals and family offices, businesses, and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services. The firm generates the key revenue from Private Client Services, which provide comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving, and trust and estate planning.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.